Context. NTQ1062 (Nanjing Chia-Tai Tianqing; CTTQ) is an oral ATP-competitive Akt inhibitor being developed for cancer. Because the PI3K/Akt/mTOR pathway is one of the most commonly disrupted pathways in…
Context. NTQ1062 (Nanjing Chia-Tai Tianqing; CTTQ) is an oral ATP-competitive Akt inhibitor being developed for cancer. Because the PI3K/Akt/mTOR pathway is one of the most commonly disrupted pathways in…